GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford BioDynamics PLC (LSE:OBD) » Definitions » Debt-to-EBITDA

Oxford BioDynamics (LSE:OBD) Debt-to-EBITDA : -0.56 (As of Sep. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Oxford BioDynamics Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Oxford BioDynamics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was £0.82 Mil. Oxford BioDynamics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was £5.62 Mil. Oxford BioDynamics's annualized EBITDA for the quarter that ended in Sep. 2023 was £-11.58 Mil. Oxford BioDynamics's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was -0.56.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Oxford BioDynamics's Debt-to-EBITDA or its related term are showing as below:

LSE:OBD' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.03   Med: -0.83   Max: -0.12
Current: -0.65

During the past 11 years, the highest Debt-to-EBITDA Ratio of Oxford BioDynamics was -0.12. The lowest was -1.03. And the median was -0.83.

LSE:OBD's Debt-to-EBITDA is ranked worse than
100% of 276 companies
in the Biotechnology industry
Industry Median: 1.355 vs LSE:OBD: -0.65

Oxford BioDynamics Debt-to-EBITDA Historical Data

The historical data trend for Oxford BioDynamics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford BioDynamics Debt-to-EBITDA Chart

Oxford BioDynamics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.12 -1.03 -1.00 -0.65

Oxford BioDynamics Semi-Annual Data
Sep13 Sep14 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.03 -1.28 -0.85 -0.71 -0.56

Competitive Comparison of Oxford BioDynamics's Debt-to-EBITDA

For the Biotechnology subindustry, Oxford BioDynamics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oxford BioDynamics's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxford BioDynamics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Oxford BioDynamics's Debt-to-EBITDA falls into.



Oxford BioDynamics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Oxford BioDynamics's Debt-to-EBITDA for the fiscal year that ended in Sep. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.818 + 5.621) / -9.841
=-0.65

Oxford BioDynamics's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.818 + 5.621) / -11.578
=-0.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Sep. 2023) EBITDA data.


Oxford BioDynamics  (LSE:OBD) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Oxford BioDynamics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Oxford BioDynamics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Oxford BioDynamics (LSE:OBD) Business Description

Traded in Other Exchanges
Address
Oxford Business Park South, 3140 Rowan Place, John Smith Drive, Oxford, GBR, OX4 2WB
Oxford BioDynamics PLC is a biotechnology company. The company focuses on the discovery and development of biomarkers for use within the pharmaceutical and biotechnology industry. It provides a technology platform Episwitch which aims to accelerate the drug discovery and development process and improve the success rate of therapeutic product development. Geographically, the majority of revenue is from The United Kingdom.

Oxford BioDynamics (LSE:OBD) Headlines

No Headlines